Methyl AminolevulinatePDT for Actinic （甲基AminolevulinatePDT光化性的）.pdfVIP

V o l u m e 1 4 • Nu m b e r 6 • J u l y / A u g u s t 2 0 0 9 I n d e x e d b y t h e U S N a t i o n a l L i b r a r y o f M e d i c i n e a n d P u b M e d Methyl Aminolevulinate-PDT for Actinic Keratoses and Superficial Nonmelanoma Skin Cancers B. Ortiz-Policarpio, MD and H. Lui, MD, FRCPC Photomedicine Institute, Department of Dermatology and Skin Science, Vancouver Coastal Health Research Institute, BC Cancer Agency, and University of British Columbia, Vancouver, BC, Canada ABSTRACT Methyl aminolevulinate-hydrochloride cream (Metvix® [in Canada] and Metvixia® [in the US], Galderma) in combination with photodynamic therapy (PDT) provides an effective treatment option for actinic keratoses (AKs), superficial basal cell carcinoma (sBCC), and Bowen’s disease (BD). Good clinical outcomes have been reported in the literature. Complete responses (CRs) in AK range from 69% to 93% at 3 months. In sBCC, reported CR rates were from 85% to 93% at 3 months and almost on par with cryo- surgery at 60 months (75% vs. 74%). In BD, CR rates were 93% at 3 months and 68% at 2 years. Current evidence has shown that this noninvasive treatment is superior in terms of cosmetic outcome to other management strategies such as surgery. It also offers the advantages of relative simplicity, low risk of side-effects and decreased complications due to scar formation. Keywords: actinic keratosis; basal cell carcinoma; Bowen’s disease; methyl aminolevulinate; PDT; photodynamic therapy 7 Topical Methyl Aminolevulinate (MAL)-PDT and AKs. MAL, the methylated ester of ALA, is a new topical Photodynamic therapy (PDT